ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA and Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Oncology Reports. ATHENS: SPANDIDOS PUBL LTD, vol. 38, No 4, p. 2535-2542. ISSN 1021-335X. doi:10.3892/or.2017.5891. 2017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas
Authors ZLÁMALÍKOVÁ, Lenka (203 Czech Republic), Mojmír MOULIS (203 Czech Republic), Barbora RAVČUKOVÁ (203 Czech Republic), Květoslava LIŠKOVÁ (203 Czech Republic), Jitka MALČÍKOVÁ (203 Czech Republic), David ŠÁLEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, guarantor, belonging to the institution), Miluše SVITÁKOVÁ (203 Czech Republic), Renata HRABÁLKOVÁ (203 Czech Republic), Jan ŠMARDA (203 Czech Republic) and Jana ŠMARDOVÁ (203 Czech Republic).
Edition Oncology Reports, ATHENS, SPANDIDOS PUBL LTD, 2017, 1021-335X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.976
RIV identification code RIV/00216224:14110/17:00097935
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3892/or.2017.5891
UT WoS 000411688200073
Keywords in English mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 18/3/2018 15:22.
Abstract
Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 29/3/2024 01:15